This study involves single doses of LY3154207 and will evaluate the effects of LY3154207 on
the body. There will be 3 parts to this study.
Part A will test single increasing doses of LY3154207 and will last approximately 7 weeks for
each participant. Each participant will receive two doses of LY3154207, if part A is
completed.
Part B will test a single dose of LY3154207 and will last approximately 5 weeks for each
participant. Part B includes collecting fluid from the spinal column to measure levels of
LY3154207.
Part C will include a single dose of LY3154207 given alone and then a second dose given along
with itraconazole to look for change in LY3154207 levels. Part C will last about 3 weeks for
each participant.
Participants may only enroll in 1 of the 3 parts of the study.